<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266055</url>
  </required_header>
  <id_info>
    <org_study_id>BLEUET 2017-135</org_study_id>
    <nct_id>NCT03266055</nct_id>
  </id_info>
  <brief_title>Effects of Blueberry on Gut Microbiota and Metabolic Syndrome</brief_title>
  <official_title>Prebiotic Effects of Blueberry in Overweight/Obese Individuals: Potential Role of the Gut Microbiota in Alleviating the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is growing evidence that nutritional intervention with dietary polyphenols can&#xD;
      positively modulate the gut microbiota to improve cardiometabolic health. Whether the&#xD;
      beneficial effects of blueberries on obesity and the metabolic syndrome can be linked to&#xD;
      their potential impact on the gut microbiota and intestinal integrity remains speculative at&#xD;
      this time. Moreover, the mechanisms of action underlying health benefits associated to&#xD;
      blueberry consumption are still unknown. The investigators are thus proposing to combine the&#xD;
      study of metagenomics, transcriptomics and metabolomics to test whether a prebiotic activity&#xD;
      of highbush blueberries can play a role in the prevention of obesity-linked metabolic&#xD;
      syndrome in a clinical setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma insulin/glucose of overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma lipids/lipoproteins of overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression in overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolites concentration in overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the gut microbiota composition in overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure of overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intestinal integrity of overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammation biomarkers of overweight/obese men and women taking either blueberry powder or placebo blueberry powder</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Gut Microbiota</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Blueberry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry placebo powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50 g of blueberry powder, taken daily for 8 weeks</intervention_name>
    <description>Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.</description>
    <arm_group_label>Blueberry powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50g of placebo blueberry powder, taken daily for 8 weeks</intervention_name>
    <description>Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).</description>
    <arm_group_label>Blueberry placebo powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and premenopause women in good health&#xD;
&#xD;
          -  Caucasians&#xD;
&#xD;
          -  At least one of the following : BMI between 25 and 40 kg/m2 or Waist circumference ≥&#xD;
             80 cm for women and ≥ 94 cm for men&#xD;
&#xD;
          -  At least one of the following : TG ≥ 1.35 mmol/L or fasting insulinemia ≥ 42 pmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metabolic disorders (hypertension, diabetes, hypercholesterolemia)&#xD;
&#xD;
          -  Regular use of medication affecting study parameters&#xD;
&#xD;
          -  Use of natural health product in the last 3 months&#xD;
&#xD;
          -  Use of antibiotics in the last 3 months&#xD;
&#xD;
          -  Nicotine users&#xD;
&#xD;
          -  Allergy or intolerance for blueberries&#xD;
&#xD;
          -  Blueberry taste aversion&#xD;
&#xD;
          -  More than 2 alcohol drinks par day&#xD;
&#xD;
          -  Particular dietary habits (vegetarism, gluten-free diet, cetogenic diet...)&#xD;
&#xD;
          -  Weight change of more than 5% in the last 3 months&#xD;
&#xD;
          -  Surgery in the last 3 months or planed during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Vohl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Québec</city>
        <zip>G1V0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Marie-Claude Vohl</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Blueberry</keyword>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

